跳至主要内容
临床试验/IRCT138806102397N1
IRCT138806102397N1已完成3 期

Comparison of safety and efficacy of Ziferon and Betaferon in patients with remitting -relapsing multiple sclerosis

Medical Vice chancellor for research, Tehran University of Science0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Inclusion Criteria:
  • 1. Patients with Remitting -Relapsing Multiple Sclerosis (RRMS ) according to M.C. Donald criteria
  • 2. Age between 18-50 years old
  • 3. Expanded Disability Status Scale (EDSS) between 0-5.5
  • 4. Completing informed consent
  • 5. No relapse during last month
  • 6. Negative pregnancy test
  • 7. Having 2 attacks during last 2 years
  • Exclusion Criteria
  • 1. Pregnancy
  • 2. Severe depression
  • 3. History of suicide
  • 4. Hypersensitivity to interferon beta preparations
  • 5. Receiving IVIG (Intravenous Immunoglobulin) in the previous 6 months
  • 6. History of plasma exchange in the last six months
  • 7. History of interferon beta using in the previous six months
  • 8. History of cytotoxic drug using in the previous six months
  • 9. Impaired liver enzymes
  • 10. Leukopenia
  • 11. Non RRMS
  • 12. Concomitant other autoimmune diseases
  • 13. History of malignancy
  • 14. Chronic liver disease except Gilbert
  • 15. Chronic renal failure (Creatinine>1.1)
  • 16. Claustrophobia
  • 17. Sensitivity to Gadolinium
  • 18. Participating in another trial
  • 19. Nursing

排除标准

  • 未提供

研究者

发起方
Medical Vice chancellor for research, Tehran University of Science

相似试验